Patents Assigned to PolaRx Biopharmaceuticals Inc.
  • Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds
    Patent number: 7205001
    Abstract: The invention relates to the use of arsenic compounds to treat a variety of neoplastic diseases. The present invention encompasses the administration to a mammal of arsenic in the form of a salt, complex, organic compound or ionic solution to treat tumors of epithelial tissue, connective tissue, central nervous system, lymphoid tissue, hematopoietic cells and tumors associated with oncogenic viruses. This invention also encompasses the treatment of hematopoietic disorders in mammals by the administration of one or more arsenic compounds to said mammal. Further, the arsenic compounds may be used to treat metastatic neoplastic diseases.
    Type: Grant
    Filed: November 3, 2003
    Date of Patent: April 17, 2007
    Assignee: Polarx Biopharmaceuticals, Inc.
    Inventors: Ralph M. Ellison, Fred H. Marmelstein
  • Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds
    Patent number: 7179493
    Abstract: The invention relates to the use of arsenic compounds to treat a variety of neoplastic diseases. The present invention encompasses the administration to a mammal of arsenic in the form of a salt, complex, organic compound or ionic solution to treat tumors of epithelial tissue, connective tissue, central nervous system, lymphoid tissue, hematopoietic cells and tumors associated with oncogenic viruses. This invention also encompasses the treatment of hematopoietic disorders in mammals by the administration of one or more arsenic compounds to said mammal. Further, the arsenic compounds may be used to treat metastatic neoplastic diseases.
    Type: Grant
    Filed: August 28, 2003
    Date of Patent: February 20, 2007
    Assignee: PolaRx Biopharmaceuticals, Inc.
    Inventors: Ralph M. Ellison, Fred H. Marmelstein
  • Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds
    Patent number: 7163703
    Abstract: The invention relates to the use of arsenic compounds to treat a variety of neoplastic diseases. The present invention encompasses the administration to a mammal of arsenic in the form of a salt, complex, organic compound or ionic solution to treat tumors of epithelial tissue, connective tissue, central nervous system, lymphoid tissue, hematopoietic cells and tumors associated with oncogenic viruses. This invention also encompasses the treatment of hematopoietic disorders in mammals by the administration of one or more arsenic compounds to said mammal. Further, the arsenic compounds may be used to treat metastatic neoplastic diseases.
    Type: Grant
    Filed: August 14, 2003
    Date of Patent: January 16, 2007
    Assignee: PolaRx Biopharmaceuticals, Inc.
    Inventors: Ralph M. Ellison, Fred H. Mermelstein
  • Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds
    Patent number: 7132116
    Abstract: The invention relates to the use of arsenic compounds to treat a variety of neoplastic diseases. The present invention encompasses the administration to a mammal of arsenic in the form of a salt, complex, organic compound or ionic solution to treat tumors of epithelial tissue, connective tissue, central nervous system, lymphoid tissue, hematopoietic cells and tumors associated with oncogenic viruses. This invention also encompasses the treatment of hematopoietic disorders in mammals by the administration of one or more arsenic compounds to said mammal. Further, the arsenic compounds may be used to treat metastatic neoplastic diseases.
    Type: Grant
    Filed: August 14, 2003
    Date of Patent: November 7, 2006
    Assignee: PolaRx Biopharmaceuticals Inc.
    Inventors: Ralph M. Ellison, Fred H. Mermelstein
  • Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds
    Patent number: 6875451
    Abstract: The invention relates to the use of arsenic compounds to treat a variety of neoplastic diseases. The present invention encompasses the administration to a mammal of arsenic in the form of a salt, complex, organic compound or ionic solution to treat tumors of epithelial tissue, connective tissue, central nervous system, lymphoid tissue, hematopoietic cells and tumors associated with oncogenic viruses. This invention also encompasses the treatment of hematopoietic disorders in mammals by the administration of one or more arsenic compounds to said mammal. Further, the arsenic compounds may be used to treat metastatic neoplastic diseases.
    Type: Grant
    Filed: October 15, 1998
    Date of Patent: April 5, 2005
    Assignee: PolaRx Biopharmaceuticals Inc.
    Inventors: Ralph M. Ellison, Fred H. Mermelstein
  • Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds
    Publication number: 20040197420
    Abstract: The invention relates to the use of arsenic compounds to treat a variety of neoplastic diseases. The present invention encompasses the administration to a mammal of arsenic in the form of a salt, complex, organic compound or ionic solution to treat tumors of epithelial tissue, connective tissue, central nervous system, lymphoid tissue, hematopoietic cells and tumors associated with oncogenic viruses. This invention also encompasses the treatment of hematopoietic disorders in mammals by the administration of one or more arsenic compounds to said mammal. Further, the arsenic compounds may be used to treat metastatic neoplastic diseases.
    Type: Application
    Filed: February 27, 2004
    Publication date: October 7, 2004
    Applicant: POLARX BIOPHARMACEUTICALS, INC.
    Inventors: Ralph M. Ellison, Fred H. Mermelstein
  • Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds
    Publication number: 20040197421
    Abstract: The invention relates to the use of arsenic compounds to treat a variety of neoplastic diseases. The present invention encompasses the administration to a mammal of arsenic in the form of a salt, complex, organic compound or ionic solution to treat tumors of epithelial tissue, connective tissue, central nervous system, lymphoid tissue, hematopoietic cells and tumors associated with oncogenic viruses. This invention also encompasses the treatment of hematopoietic disorders in mammals by the administration of one or more arsenic compounds to said mammal. Further, the arsenic compounds may be used to treat metastatic neoplastic diseases.
    Type: Application
    Filed: February 27, 2004
    Publication date: October 7, 2004
    Applicant: POLARX BIOPHARMACEUTICALS, INC
    Inventors: Ralph M. Ellison, Fred H. Mermelstein
  • Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds
    Publication number: 20040161475
    Abstract: The invention relates to the use of arsenic compounds to treat a variety of neoplastic diseases. The present invention encompasses the administration to a mammal of arsenic in the form of a salt, complex, organic compound or ionic solution to treat tumors of epithelial tissue, connective tissue, central nervous system, lymphoid tissue, hematopoietic cells and tumors associated with oncogenic viruses. This invention also encompasses the treatment of hematopoietic disorders in mammals by the administration of one or more arsenic compounds to said mammal. Further, the arsenic compounds may be used to treat metastatic neoplastic diseases.
    Type: Application
    Filed: February 12, 2004
    Publication date: August 19, 2004
    Applicant: PolaRx Biopharmaceuticals, Inc.
    Inventors: Ralph M. Ellison, Fred H. Marmelstein
  • Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds
    Publication number: 20040115283
    Abstract: The invention relates to the use of arsenic compounds to treat a variety of neoplastic diseases. The present invention encompasses the administration to a mammal of arsenic in the form of a salt, complex, organic compound or ionic solution to treat tumors of epithelial tissue, connective tissue, central nervous system, lymphoid tissue, hematopoietic cells and tumors associated with oncogenic viruses. This invention also encompasses the treatment of hematopoietic disorders in mammals by the administration of one or more arsenic compounds to said mammal. Further, the arsenic compounds may be used to treat metastatic neoplastic diseases.
    Type: Application
    Filed: August 28, 2003
    Publication date: June 17, 2004
    Applicant: PolaRx Biopharmaceuticals, Inc.
    Inventors: Ralph M. Ellison, Fred H. Marmelstein
  • Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds
    Publication number: 20040096518
    Abstract: The invention relates to the use of arsenic compounds to treat a variety of neoplastic diseases. The present invention encompasses the administration to a mammal of arsenic in the form of a salt, complex, organic compound or ionic solution to treat tumors of epithelial tissue, connective tissue, central nervous system, lymphoid tissue, hematopoietic cells and tumors associated with oncogenic viruses. This invention also encompasses the treatment of hematopoietic disorders in mammals by the administration of one or more arsenic compounds to said mammal. Further, the arsenic compounds may be used to treat metastatic neoplastic diseases.
    Type: Application
    Filed: November 3, 2003
    Publication date: May 20, 2004
    Applicant: PolaRx Biopharmaceuticals, Inc.
    Inventors: Ralph M. Ellison, Fred H. Mermelstein
  • Compositions and methods for the treatme of primary and metastatic neoplastic disea using arsenic compounds
    Publication number: 20040047916
    Abstract: The invention relates to the use of arsenic compounds to treat a variety of neoplastic diseases. The present invention encompasses the administration to a mammal of arsenic in the form of a salt, complex, organic compound or ionic solution to treat tumors of epithelial tissue, connective tissue, central nervous system, lymphoid tissue, hematopoietic cells and tumors associated with oncogenic viruses. This invention also encompasses the treatment of hematopoietic disorders in mammals by the administration of one or more arsenic compounds to said mammal. Further, the arsenic compounds may be used to treat metastatic neoplastic diseases.
    Type: Application
    Filed: August 28, 2003
    Publication date: March 11, 2004
    Applicant: PolaRx Biopharmaceuticals, Inc.
    Inventors: Ralph M. Ellison, Fred H. Marmelstein